Inmune Bio, Inc. — Form 8-K
Filed July 31, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
On July 30, 2026, INmune Bio received approximately $4.2M in R&D cash rebates from Australia, plus $0.4M from the United Kingdom in June 2026, totaling $4.6M in non-dilutive funding. These rebates, generated through established government programs for qualifying R&D expenditures in clinical development, manufacturing, and regulatory activities, exceeded the company's Q2 net operating cash burn and extend cash runway for advancing CORDStrom toward regulatory filings.
Why this rating
9% of market cap in non-dilutive cash meaningfully extends runway for pre-revenue biotech; significant relative to company size, though not transformational for core pipeline execution risk.
See more from July 31, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.